

Notice Regarding Adjustment of 340B Prices for Select Products of Kedrion Biopharma Inc.

Kedrion Biopharma Inc. (“Kedrion”) has recalculated its 340B ceiling prices for certain products for the period Q3 2014 through Q4 2018 (the “Restatement Period”). The products impacted are listed below. The recalculation of ceiling prices is due to revisions made to the Medicaid pricing data for the products listed for the period Q1 2014 through Q2 2018.

Kedrion has asked the Office of Pharmacy Affairs (“OPA”) to post the notice to the OPA public website to ensure transparency by providing access to information regarding Kedrion’s recalculation, and potential overpayments by certain 340B Covered Entities (“Covered Entity”), for impacted Kedrion products related thereto. In the event that Kedrion data demonstrates that a Covered Entity overpaid by **\$10 or more** in the aggregate for the impacted products during the Restatement Period, Kedrion will work through Apexus, LLC (“Apexus”) to issue refunds to those Covered Entities.

However, should Kedrion data demonstrate that a Covered Entity overpaid by less than **\$10** in the aggregate for the impacted products during the Restatement Period, Kedrion will not issue a refund to such Covered Entity on its own accord. If a Covered Entity believes that it has overpaid by less than \$10 in the aggregate for the impacted products during the Restatement Period, and the Covered Entity would like to request a refund, such Covered Entity should contact Kedrion directly via email at 340BProgram@kedrion.com. If a Covered Entity is not contacted by May 31, 2019, then it has been determined that the organization’s overpayments are below the \$10 impact level. The Covered Entity may contact Kedrion as directed to obtain a refund, and Kedrion will accept requests received on or before July 31, 2019.

Kedrion will issue a refund for an aggregate overpayment of less than \$10 by a Covered Entity for the impacted products during the Restatement Period upon its timely receipt of the Covered Entity’s request, and validation of the same.

NDC	Product Description
00562-7805-01	RhoGAM Ultra Filtered Plus
00562-7805-05	RhoGAM Ultra Filtered Plus
00562-7805-25	RhoGAM Ultra Filtered Plus
00562-7806-01	MICRhoGAM Ultra Filtered Plus
00562-7806-05	MICRhoGAM Ultra Filtered Plus
00562-7806-25	MICRhoGAM Ultra Filtered Plus
76125-0250-20	Koate DVI 250 IU Powder for Injection
76125-0256-20	Koate 250 IU Powder for Injection
76125-0667-30	Koate DVI 500 IU Powder for Injection
76125-0667-50	Koate DVI 1000 IU Powder for Injection
76125-0668-30	Koate 500 IU Powder for Injection
76125-0676-50	Koate 1000 IU Powder for Injection
76125-0784-10	Albuked 25% Solution for Injection
76125-0784-25	Albuked 25% Solution for Injection
76125-0785-25	Albuked 5% Solution for Injection
76125-0790-25	Albuked 5% Solution for Injection
76125-0792-10	Albuked 25% Solution for Injection
76125-0792-25	Albuked 25% Solution for Injection
76125-0900-01	Gammaked 10% Solution for Injection
76125-0900-10	Gammaked 10% Solution for Injection
76125-0900-20	Gammaked 10% Solution for Injection
76125-0900-50	Gammaked 10% Solution for Injection
76179-0025-02	Kedbumin 25% Solution for Injection
76179-0025-04	Kedbumin 25% Solution for Injection